Wegovy vs Ozempic — same drug, different label
Quick read · 5 min
Wegovy and Ozempic both contain semaglutide made by Novo Nordisk. The active ingredient is identical. But they have different FDA approvals: Wegovy for weight loss, Ozempic for type 2 diabetes. This difference in labels affects weight loss results, dose ceilings, pricing, and insurance coverage.
- •Wegovy and Ozempic are the same active drug (semaglutide) but different FDA labels: Wegovy for weight loss, Ozempic for diabetes
- •Wegovy reaches 2.4mg weekly, Ozempic caps at 2.0mg, but the dose difference is small
- •Weight loss looks different: Wegovy ~14.9%, Ozempic ~6%. This is because Wegovy trials tested non-diabetics (lose more), Ozempic trials tested people with diabetes (lose less)
- •Insurance covers Wegovy for weight loss, Ozempic for diabetes only. Ozempic for weight loss is off-label and usually not covered
- •Cheapest option: Wegovy pill ~$149/month. Most expensive: Wegovy injection ~$1,349/month
Based on clinical trials · No rankings · Every claim linked to source
Same drug, different brand
Both Wegovy and Ozempic contain semaglutide made by the same company. The only material difference is the FDA approval label — Wegovy is labeled for weight loss, Ozempic is labeled for diabetes. This label difference determines maximum dose, insurance coverage, and how the drugs were tested.
Side by side
Wegovy
- Approved for: Weight loss in obesity and overweight with health conditions
- Max dose: 2.4mg weekly
- Weight loss: ~14.9% average in trials
- Forms available: Injection weekly OR pill daily
- List price: ~$1,349/month (injection), ~$149/month (pill)
Ozempic
- Approved for: Type 2 diabetes
- Max dose: 2.0mg weekly
- Weight loss: ~6% average in trials
- Forms available: Injection only
- List price: ~$968/month
Complete comparison
| Feature | Wegovy | Ozempic |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA-approved use | Weight loss (obesity / overweight with conditions) | Type 2 diabetes |
| Max dose (weekly) | 2.4mg injection | 2.0mg injection |
| Weight loss in trials | ~14.9% (non-diabetics) | ~6% (people with diabetes) |
| Trial population | Adults with obesity, no diabetes | Adults with type 2 diabetes |
| Available forms | Weekly injection + daily pill | Weekly injection only |
| List price | ~$1,349/month (injection) | ~$968/month |
| Cheapest option | ~$149/month (pill) | No cheaper form available |
| Insurance coverage | If you have obesity / overweight with conditions | If you have type 2 diabetes (not weight loss) |
Why does the same drug have two names?
When companies develop a new drug, they get FDA approval for a specific medical use — called an indication. Novo Nordisk discovered that semaglutide worked for both type 2 diabetes and weight loss, so they pursued separate FDA approvals for each.
Ozempic was approved first for diabetes. Years later, Novo Nordisk conducted new trials for weight loss, submitted the data to the FDA, and in 2021, secured approval under a different brand name — Wegovy — specifically for weight loss.
Both brands are made from the same active ingredient by the same company. What differs is the FDA label, which determines:
- •Maximum dose: Wegovy goes to 2.4mg weekly (for weight loss); Ozempic to 2.0mg weekly (for diabetes)
- •Insurance coverage: Insurance covers medications for their FDA-approved uses only
- •Clinical evidence: Different trials with different populations
Why Wegovy shows more weight loss
Trial results look very different: Wegovy ~14.9% vs Ozempic ~6%. But this does NOT mean Wegovy is a stronger drug.
The real reason:
People with type 2 diabetes lose significantly less weight on GLP-1 drugs than people without diabetes. Ozempic was studied in people with diabetes (~6% weight loss). Wegovy was studied in people without diabetes (~14.9% weight loss). The drug is the same; the trial populations are different.
If you gave Ozempic to non-diabetics, they would lose more weight. If you gave Wegovy to diabetics, they would lose less. The dose difference (2.4mg vs 2.0mg) plays a small role, but population biology is the dominant reason for the gap.
The insurance reality
Some people ask if they can use Ozempic for weight loss instead of Wegovy, hoping insurance will cover it because it's cheaper. Here's why this usually doesn't work:
- 1.Insurance covers approved uses. Ozempic is approved for type 2 diabetes, not weight loss. Using it for weight loss is called an off-label use.
- 2.Insurance rarely covers off-label uses. Some plans have exceptions for very specific cases, but weight loss without diabetes is not typically covered.
- 3.Wegovy is the covered option. If your insurance covers semaglutide for weight loss, they will cover Wegovy (the approved brand for that use).
Bottom line: If you have obesity or overweight with a qualifying health condition, ask your doctor about Wegovy. It's the weight-loss-approved brand and far more likely to be covered by insurance.
Which should I ask my doctor about?
This depends on your health status and insurance:
If you have obesity (or overweight with a health condition):
Ask about Wegovy. It's FDA-approved for your situation and far more likely to be covered by insurance.
If you have both type 2 diabetes and obesity:
Your doctor may recommend Ozempic (for diabetes management) or Wegovy (for weight loss). Both are options — discuss which makes sense for your insurance and goals.
If cost is your biggest concern:
Consider Wegovy pill (~$149/month), which is far cheaper than either injection form and approved for weight loss.
Next step most people take
Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: March 2026